LGVN Longeveron

Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

MIAMI, Nov. 04, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report third quarter 2024 financial results and provide a business update on Tuesday, November 12, 2024 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET.

Conference Call Details:

Conference Call Number:1.877.407.0789
Conference ID:13749428
  
Call me™ Feature:
Webcast:
  

An archived replay of the webcast will be available on the “” section of the Company’s website following the conference.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s Disease (AD), and Aging-related Frailty. Lomecel-B™ development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit or follow Longeveron on , , and .

Investor Contact:

Derek Cole

Investor Relations Advisory Solutions



EN
04/11/2024

Underlying

LGVNLongeveron

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Longeveron

 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron Granted Chinese Patent for Potency Assay Methods for Assess...

Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) The patent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, peripheral blood, a lung, a heart, amniotic fluid, inner organs, an amniotic membrane, an umbilical cord or a placenta or differentiated from induced pluripotent stem cells (IPSCs)Patent issuance contributes to Longeveron’s growing international portfolio of 52 patents protecting its clinical programs and products globallyLaromestrocel development p...

April 8, 2026 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron Announces 2025 Full Year Financial Results and Provides Bus...

Longeveron Announces 2025 Full Year Financial Results and Provides Business Update On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS II may serve as foundation for a Biologics License Application (BLA) submission for full approval for HLHS, if results demonstrate sufficient evidence of efficacyClosed a private placement of up to $30 million, with $15 million funded in the initial closing, led by Co...

March 17, 2026 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron to Report 2025 Full-Year Financial Results and Host Confere...

Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026 MIAMI, March 12, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report 2025 full year financial results and provide a business update on Tuesday, March 17, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details: Conference ...

March 12, 2026 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron Announces Closing of Private Placement of up to $30 Million

Longeveron Announces Closing of Private Placement of up to $30 Million $15 million upfront with a milestone-driven potential additional $15 million related to the Company’s anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market under Nasdaq rules Private placement led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsInitial proceeds extend cash runway into 4Q26, past the anticipated pivotal Phase 2b ELPIS II clinical trial 3Q26 topline data readout MIAMI, March 11, 2026 (GLOBE NEWSWIRE) --...

March 11, 2026 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron Announces Private Placement of up to $30 Million

Longeveron Announces Private Placement of up to $30 Million $15 million upfront with a milestone-driven potential additional $15 million related to the Company’s anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market under Nasdaq rules Private placement led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsInitial proceeds extend cash runway into 4Q26, past the anticipated pivotal Phase 2b ELPIS II clinical trial 3Q26 topline data readout MIAMI, March 10, 2026 (GLOBE NEWSWIRE) -- Longeveron...

March 10, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch